Abstract 19P
Background
Triple-negaive breast cancer (TNBC) is a highly aggressive subtype with neoadjuvant options historically limited to chemotherapy until the recent success of the KEYNOTE-522 trial. Although TNBC is well known for being associated with constitutional pathogenic BRCA mutations when compared to other types of breast cancer, the genetic profiles of the patients in the KEYNOTE-522 trial are unknown and no subgroup analysis has assessed a possible relationship with treatment efficacy.
Methods
We analysed consecutive index-case genetic consults of TNBC patients (N = 170) between January 2020 and July 2024 in our oncogenetics department. Only patients with treatment history in our center were included. Tumor characteristics, pCR status and the type of chemotherapy agents used were collected. We compared the pCR and non pCR rates according to the genetic status and survival probability distribution stratified by the presence or not of Pembrolizumab and Carboplatin using Fisher’s exact test and the Kaplan-Meier method. A significance threshold of 5% was applied to all statistical analyses.
Results
A total of 132 patients were identified for the analysis. Significant benefits were observed in patients with pCR in terms of EFS (p = 0.001, HR = 0.07 CI 95% 0.02 – 0.21) and OS (p = 0.012, HR = 0.12 CI 95% 0.03 – 0.50), respectively. When comparing patients treated by a neoadjuvant chemotherapy regimen to those treated by pembrolizumab plus chemotherapy, a significantly higher pCR rate was observed with the latter group (p = 0.01). Regarding the presence of pathogenic variants (PV), the following were identified: BRCA1 (N = 10), BRCA2 (N = 3), PALB 2 (N = 1), PMS2 (N = 1), RAD51C (N = 3) and RAD51D (N = 1). 30 patients carried various variants of unknown significance. Notably, all patients carrying a BRCA PV treated with pembrolizumab achieved pCR but results were not statistically significant (p = 0.14).
Conclusions
To our knowledge this is the first descriptive analysis of the genetic landscape of patients with an indication for neoadjuvant Pembrolizumab. Interestingly, all patients carrying pathogenic variants of BRCA treated with pembrolizumab had pCR although results were not statistically significant compared to patients not presenting BRCA PV.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - Anti-CTLA4 therapy leads to early expansion of peripheral Th17 population and induction of Th1 cytokines
Presenter: Mari Nakazawa
Session: Poster Display session
Resources:
Abstract
196P - Single-cell analysis of stage-I high-grade serous ovarian carcinoma reveals the essential role of regulatory T cells in early tumor establishment
Presenter: Joanna Mikulak
Session: Poster Display session
Resources:
Abstract
197P - Comprehensive immunoprofiling of the intratumoral and peripheral T cell receptor gene repertoire in triple-negative breast cancer patients
Presenter: Antonios Mingos
Session: Poster Display session
Resources:
Abstract
198P - Association of types of treatment modalities with expression of T Lymphocytes (CD4, CD8, Treg) in breast cancer patients and their clinical outcome
Presenter: Arshi Rizwan
Session: Poster Display session
Resources:
Abstract
199P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Poster Display session
Resources:
Abstract
200P - CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant NSCLC
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
201P - Underlying mechanisms of neutrophil-mediated immunosuppression and resistance to treatment in breast cancer: Further evidence that these cells matter
Presenter: Bruna Filipa Correia
Session: Poster Display session
Resources:
Abstract
202P - Mining tumor infiltrating B cells to discover antibody-target pairs and develop novel therapies
Presenter: Matthieu Delince
Session: Poster Display session
Resources:
Abstract
203P - Targeting IL-33 reprograms tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Presenter: Xuyao Zhang
Session: Poster Display session
Resources:
Abstract
204P - Deciphering the crosstalk between tumor and circulating immune microenvironment in advanced NSCLC patients undergoing immunotherapy
Presenter: Prisca Tamarozzi
Session: Poster Display session
Resources:
Abstract